Hyperthyroidism and thyroid autoimmunity induced by sorafenib in metastatic renal cell cancer.

作者信息

Konca Degertekin Ceyla, Coşkun Uğur, Baloş Törüner Füsun, Aktürk Müjde, Demirci Umut

出版信息

Endocrine. 2012 Dec;42(3):756-7. doi: 10.1007/s12020-012-9683-2.

DOI:10.1007/s12020-012-9683-2

PMID:22562706

Abstract

摘要

相似文献

Hyperthyroidism and thyroid autoimmunity induced by sorafenib in metastatic renal cell cancer.

Endocrine. 2012 Dec;42(3):756-7. doi: 10.1007/s12020-012-9683-2.

Evaluation of First-Line Sorafenib Treatment for Metastatic Renal Cell Carcinoma in Kidney Transplant Patients: A Single-Center Experience With Four Cases.

Ther Apher Dial. 2017 Aug;21(4):414-416. doi: 10.1111/1744-9987.12544. Epub 2017 Jun 8.

A Case of Pancreatic Side Effects Resulting from Sorafenib and Axitinib Treatment of Stage IV Renal Cell Carcinoma.

Keio J Med. 2015;64(4):62-4. doi: 10.2302/kjm.2015-0001-CR.

Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis.

Oncotarget. 2016 May 10;7(19):27044-54. doi: 10.18632/oncotarget.7395.

Clinical significance of sunitinib-associated macrocytosis in metastatic renal cell carcinoma.

Cancer Med. 2016 Dec;5(12):3386-3393. doi: 10.1002/cam4.919. Epub 2016 Oct 19.

Pituitary metastasis from a renal cell carcinoma progressed after sorafenib treatment.

Chin J Cancer. 2013 Jun;32(6):353-6. doi: 10.5732/cjc.012.10184. Epub 2012 Dec 7.

Stevens-Johnson syndrome induced by sorafenib for metastatic renal cell carcinoma.

Urol Int. 2013;91(4):482-3. doi: 10.1159/000351918. Epub 2013 Aug 16.

Pneumatosis intestinalis and hepatic portal venous gas in a patient receiving sorafenib.

Int J Urol. 2012 Nov;19(11):1041-2. doi: 10.1111/j.1442-2042.2012.03099.x. Epub 2012 Jul 13.

Efficacy and Safety of Sorafenib Therapy on Metastatic Renal Cell Carcinoma in Korean Patients: Results from a Retrospective Multicenter Study.

PLoS One. 2015 Aug 26;10(8):e0135165. doi: 10.1371/journal.pone.0135165. eCollection 2015.

Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.

Chemotherapy. 2012;58(6):468-74. doi: 10.1159/000346484. Epub 2013 Mar 20.

引用本文的文献

Sorafenib-induced Thyroiditis in FMS-like Tyrosine Kinase 3-internal Tandem Duplication-mutated Acute Myeloid Leukemia.

Chin Med J (Engl). 2016 Oct 20;129(20):2512-2513. doi: 10.4103/0366-6999.191831.

Auto-immune thyroid dysfunction induced by tyrosine kinase inhibitors in a patient with recurrent chordoma.

BMC Cancer. 2016 Aug 24;16(1):679. doi: 10.1186/s12885-016-2705-3.

Kinase inhibitors and monoclonal antibodies in oncology: clinical implications.

Nat Rev Clin Oncol. 2016 Apr;13(4):209-27. doi: 10.1038/nrclinonc.2015.213. Epub 2015 Dec 31.

Tyrosine kinase inhibitors induced thyroid dysfunction: a review of its incidence, pathophysiology, clinical relevance, and treatment.

Biomed Res Int. 2013;2013:725410. doi: 10.1155/2013/725410. Epub 2013 Oct 27.

本文引用的文献

Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: a prospective evaluation.

Urol Oncol. 2010 Sep-Oct;28(5):515-9. doi: 10.1016/j.urolonc.2009.08.011. Epub 2009 Nov 13.

Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients.

Clin Cancer Res. 2008 Oct 15;14(20):6674-82. doi: 10.1158/1078-0432.CCR-07-5212.

Thyrotoxicosis during sunitinib treatment for renal cell carcinoma.

Clin Endocrinol (Oxf). 2008 Oct;69(4):669-72. doi: 10.1111/j.1365-2265.2008.03253.x. Epub 2008 Apr 3.

Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib.

Ann Oncol. 2008 Feb;19(2):265-8. doi: 10.1093/annonc/mdm483. Epub 2007 Oct 24.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验